HIV-Positive Pregnant Women Who Receive Tenofovir, Emtricitabine During Childbirth Have Decreased Risk of Developing Drug Resistance, Study Says
November 8, 2007
HIV-positive women who are pregnant and receive the antiretrovirals tenofovir and emtricitabine during childbirth could reduce the risk of developing resistance to antiretroviral drugs, according to a study published Wednesday in the Lancet, AFP/Yahoo! News reports (AFP/Yahoo! News, 11/7).
Women assigned to take tenofovir and emtricitabine during childbirth were 53% less likely than women in the control group to have developed drug resistance six weeks after delivery, the study found. Women in the tenofovir-emtricitabine group had a 12% chance of developing drug resistance, compared with a 25% risk for the control group.
Four women in each group experienced postpartum anemia, and 10% of infants in the tenofovir-emtricitabine group and 12% in the control group had adverse side effects, including septicemia and pneumonia, according to the study (Lancet, 11/7). The researchers said the side effects likely were not the result of the new drug combination.
Merck's Canceled HIV Vaccine Might Have Increased Trial Participants' Risk of Becoming HIV-Positive, Researchers Say
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.